Novavax NVAX is scheduled to report third-quarter 2024 earnings on Nov. 12, before the opening bell. In the last reported ...

Novavax has inked another settlement for a past COVID-19 vaccine supply deal. | Novavax has inked another settlement for a ...

Novavax also said during its latest earnings report that it would unveil an "expanded clinical pipeline" by year-end. So, what does all this mean for investors? Novavax remains in a period of ...

With limited significant news expected from Novavax’s pipeline to add value in the near future, the shares are anticipated to underperform in the mid-term. The calculated price target of $9 by ...

Besides Sanofi deal for nuvaxovid, Novavax has few opportunities to generate additional revenue, which likely means its stock ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M adjuvant, today ...

keeping part of its pipeline intact for now. For investors, this could introduce near-term uncertainty, but it's worth noting Novavax's proactive response and its solid track record in vaccine ...

Novavax NVAX has skyrocketed 211.2% in the ... NVAX as it provides the management with funds to support its ongoing pipeline programs. Per the deal, the company is eligible to receive milestone ...

B.Riley Financial analyst Mayank Mamtani has maintained their neutral stance on MGNX stock, giving a Hold rating today. Mayank Mamtani’s ...

Dr. Draghia-Akli's ability to identify real public health needs and find the intersection with Novavax's unique technology will be critical as the Company transitions to an R&D focus with a new, ...